Enantioselective process for the preparation of both enantiomers of 10,11-dihydro-10-hydroxy-5H-dibenz [b,f]azepine-5-carboxamide and new crystal forms thereof

Details for Australian Patent Application No. 2003276055 (hide)

Owner Novartis AG

Inventors Sedelmeier, Gottfried; Grimler, Dominique; Pfeffer, Sabine; Blatter, Fritz; Mathes, Christian

Agent Davies Collison Cave

Pub. Number AU-B-2003276055

PCT Number PCT/EP03/11034

PCT Pub. Number WO2004/031155

Priority 0223224.7 07.10.02 GB

Filing date 6 October 2003

Wipo publication date 23 April 2004

Acceptance publication date 3 January 2008

International Classifications

C07D 223/24 (2006.01) Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom

A61P 25/08 (2006.01) Drugs for disorders of the nervous system

C07F 15/00 (2006.01) Compounds containing elements of the 8th Group of the Periodic System

Event Publications

19 February 2004 Complete Application Filed

  Priority application(s): 0223224.7 07.10.02 GB

27 May 2004 Application Open to Public Inspection

  Published as AU-B-2003276055

3 January 2008 Application Accepted

  Published as AU-B-2003276055

8 May 2008 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under reg. 22.2I(2). This application has been accepted or advertised accepted. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2003276056-PIPERIDINE DERIVATIVES AS CCR5 INHIBITORS

2003276054-METHOD FOR THE PRODUCTION OF POWDERED ACTIVE SUBSTANCE FORMULATIONS BY MEANS OF COMPRESSIBLE FLUIDS